EGFR and in situ carcinoma: However, it is interesting that the mTMB was significantly lower in EGFR-mutant SCC than EGFR wild-type SCC (7.61 vs. 11.9 mutations/Mb, P=0.001), the mTMB was 7.61 (95% CI: 5.84–13.40) and 11.90 (95% CI: 10.72–14.96) mutations/Mb, respectively (Figure 3D). The CIS was similar between EGFR-mutant SCC and adenocarcinoma (P = 0.251).